KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Common Equity (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Common Equity data on record, last reported at $3.2 billion in Q4 2025.

  • For Q4 2025, Common Equity fell 8.72% year-over-year to $3.2 billion; the TTM value through Dec 2025 reached $3.2 billion, down 8.72%, while the annual FY2025 figure was $3.2 billion, 8.72% down from the prior year.
  • Common Equity reached $3.2 billion in Q4 2025 per CRL's latest filing, down from $3.4 billion in the prior quarter.
  • Across five years, Common Equity topped out at $3.8 billion in Q3 2024 and bottomed at $2.2 billion in Q1 2021.
  • Average Common Equity over 5 years is $3.1 billion, with a median of $3.2 billion recorded in 2025.
  • Peak YoY movement for Common Equity: skyrocketed 32.25% in 2021, then decreased 12.23% in 2025.
  • A 5-year view of Common Equity shows it stood at $2.5 billion in 2021, then increased by 17.41% to $3.0 billion in 2022, then rose by 20.84% to $3.6 billion in 2023, then fell by 3.76% to $3.5 billion in 2024, then decreased by 8.72% to $3.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $3.2 billion in Q4 2025, $3.4 billion in Q3 2025, and $3.4 billion in Q2 2025.